We further demonstrated that miR‐186 directly targeted METTL3 and ectopic overexpression of miR‐186 significantly inhibited aggressive tumour phenotypes of HB, both in vitro and in vivo. The gene discussed is METTL3; the disease is hemoglobin measurement.